Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

RET rearrangement

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

RET amplification (1)

RET exon 11 deletion (1)

RET amplification (1)

RET exon 11 deletion (1)

›

RET rearrangement	Non Small Cell Lung Cancer	RET rearrangement	Non Small Cell Lung Cancer	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2
RET rearrangement	Non Small Cell Lung Cancer	RET rearrangement	Non Small Cell Lung Cancer	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
RET rearrangement	Non Small Cell Lung Cancer	RET rearrangement	Non Small Cell Lung Cancer	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
RET rearrangement	Non Small Cell Lung Cancer	RET rearrangement	Non Small Cell Lung Cancer	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2
RET rearrangement	Non Small Cell Lung Cancer	RET rearrangement	Non Small Cell Lung Cancer	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2
RET rearrangement	Non Small Cell Lung Cancer	RET rearrangement	Non Small Cell Lung Cancer	vandetanib Sensitive: C3 – Early Trials vandetanib Sensitive : C3	vandetanib Sensitive: C3 – Early Trials vandetanib Sensitive : C3
RET rearrangement	Non Small Cell Lung Cancer	RET rearrangement	Non Small Cell Lung Cancer	selpercatinib + pralsetinib Sensitive: C3 – Early Trials selpercatinib + pralsetinib Sensitive : C3	selpercatinib + pralsetinib Sensitive: C3 – Early Trials selpercatinib + pralsetinib Sensitive : C3
RET rearrangement	Lung Adenocarcinoma	RET rearrangement	Lung Adenocarcinoma	cabozantinib tablet Sensitive: C3 – Early Trials cabozantinib tablet Sensitive : C3	cabozantinib tablet Sensitive: C3 – Early Trials cabozantinib tablet Sensitive : C3
RET rearrangement	Thyroid Gland Carcinoma	RET rearrangement	Thyroid Gland Carcinoma	selumetinib Sensitive: D – Preclinical selumetinib Sensitive : D	selumetinib Sensitive: D – Preclinical selumetinib Sensitive : D
RET rearrangement	Thyroid Gland Papillary Carcinoma	RET rearrangement	Thyroid Gland Papillary Carcinoma	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D	MK-2206 Sensitive: D – Preclinical MK-2206 Sensitive : D
RET rearrangement	Thyroid Gland Carcinoma	RET rearrangement	Thyroid Gland Carcinoma	AZD1480 Sensitive: D – Preclinical AZD1480 Sensitive : D	AZD1480 Sensitive: D – Preclinical AZD1480 Sensitive : D